Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Whole Genome Sequencing to Detect Small Deletions in Ribosomal Protein Genes in Diamond Blackfan Anemia Patients

Jens Lichtenberg, Jason E. Farrar, MD, David Chelimo, Frederick Horne, NISC Comparative Sequencing Program, Steven Ellis, PhD, Adrianna Vlachos, MD, Jeffrey H. Lipton, PhD MD FRCPC, David M. Bodine, PhD

Blood (2017) 130 (Supplement 1): 1174.

https://doi.org/10.1182/blood.V130.Suppl_1.1174.1174

Published: 2017

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

Journal Articles

Outcome of Patients with Secondary Leukemias Managed with Different Treatment Strategies at a Single Center.

Arwa A.N. Abdelhameed, MBBS, ABIM, Joseph M. Brandwein, MD, Kathy Chun, PhD, Vikas Gupta, MD, Suzanne Kamel-Reid, MA, PhD, Jeffrey H. Lipton, PhD, MD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Andre C. Schuh, MD, Hans A. Messner, MD, PhD

Blood (2005) 106 (11): 2249.

https://doi.org/10.1182/blood.V106.11.2249.2249

Published: 2005

NARROW

Whole Genome Sequencing to Detect Small Deletions in Ribosomal Protein Genes in Diamond Blackfan Anemia Patients

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Outcome of Patients with Secondary Leukemias Managed with Different Treatment Strategies at a Single Center.

Email alerts

ASH Publications

American Society of Hematology

Whole Genome Sequencing to Detect Small Deletions in Ribosomal Protein Genes in Diamond Blackfan Anemia Patients

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Outcome of Patients with Secondary Leukemias Managed with Different Treatment Strategies at a Single Center.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only